IDNA Genomics (IDNA) Stock Overview
Engages in the field of genomics and biotechnology and specializes in personalized health care. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
IDNA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
IDNA Genomics Public Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €29.00 |
| 52 Week High | €29.40 |
| 52 Week Low | €27.00 |
| Beta | 0.0035 |
| 1 Month Change | -1.36% |
| 3 Month Change | 5.84% |
| 1 Year Change | 7.41% |
| 3 Year Change | 9.85% |
| 5 Year Change | n/a |
| Change since IPO | 20.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| IDNA | CY Healthcare | CY Market | |
|---|---|---|---|
| 7D | 0% | 0.9% | -2.1% |
| 1Y | 7.4% | -1.0% | 57.1% |
Return vs Industry: IDNA exceeded the CY Healthcare industry which returned -1% over the past year.
Return vs Market: IDNA underperformed the CY Market which returned 56.6% over the past year.
Price Volatility
| IDNA volatility | |
|---|---|
| IDNA Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in CY Market | 13.8% |
| 10% least volatile stocks in CY Market | 3.2% |
Stable Share Price: IDNA's share price has been volatile over the past 3 months compared to the CY market.
Volatility Over Time: Insufficient data to determine IDNA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 21 | n/a | www.idnagenomicsplc.com |
IDNA Genomics Public Ltd engages in the field of genomics and biotechnology and specializes in personalized health care. The company develops and provides genetic tests in the field of genomics. It also develops and markets pharmaceutical products.
IDNA Genomics Public Ltd Fundamentals Summary
| IDNA fundamental statistics | |
|---|---|
| Market cap | €80.05m |
| Earnings (TTM) | -€2.51m |
| Revenue (TTM) | €512.70k |
Is IDNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IDNA income statement (TTM) | |
|---|---|
| Revenue | €512.70k |
| Cost of Revenue | €502.51k |
| Gross Profit | €10.19k |
| Other Expenses | €2.52m |
| Earnings | -€2.51m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 1.99% |
| Net Profit Margin | -489.80% |
| Debt/Equity Ratio | -142.8% |
How did IDNA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/20 03:09 |
| End of Day Share Price | 2025/10/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IDNA Genomics Public Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.